Lab-Grown Vessel Beats Standard Fistula for Dialysis
A new Humacyte trial shows lab-grown vessels provide faster dialysis access for women than traditional surgical fistulas.
Updated on Oct. 28, 2026 in Stroke
Live Poll
Do you trust new medical technologies over established surgical procedures for your healthcare?
Humacyte reported interim Phase 3 trial results demonstrating that lab-grown vessels enable dialysis access significantly faster than standard arteriovenous fistulas in women. The study found these vessels reduced the reliance on high-risk infection-prone catheters.
Why it matters
Women often face lower success rates with traditional fistulas due to smaller blood vessels, leading to prolonged catheter use and higher infection risks. This lab-grown alternative offers a potentially safer and more efficient pathway for long-term dialysis access.
In this interim Phase 3 trial of 80 women, those with lab-grown vessels spent 220 days catheter-free over one year compared to 129 days for the fistula group. The infection rate for the vessel group was 6 per 100 patient-years versus 23 per 100 patient-years for fistulas.
The players
Humacyte
This biotechnology company focuses on developing universal, off-the-shelf, lab-grown tissue-engineered therapies for vascular and other medical conditions.
FDA
The Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices to ensure public health safety in the United States.
The details
Surgeons create access by connecting the lab-grown vessel between an artery and a vein, whereas a traditional fistula requires connecting a patient's own vessels. Because only 65% of fistulas typically mature within 12 months, this alternative aims to shorten the time until the access is usable.
Timeline
December 2024: The FDA approved the vessel as Symvess for vascular trauma.
June 2026: Humacyte announced the initial topline trial results.
October 2026: Results were presented at an American Society of Nephrology meeting in Denver.
Q4 2026: Humacyte plans to submit an FDA label expansion application.
Health Landscape
This development follows the established regulatory process for gaining new clinical indications for previously cleared medical devices under the FDA's medical device approval pathways. It highlights a shift in how biotech firms are expanding the reach of lab-grown tissue products.
This treatment could significantly reduce the time women on dialysis must rely on infection-prone catheters by providing faster, more reliable vascular access. Patients should consult with their nephrologists to track if and when this technology becomes available for wider clinical use.
The takeaway
The use of bioengineered vessels could fundamentally change the standard of care for dialysis patients who struggle with traditional fistula maturation. Providing patients with more robust access options may significantly lower the incidence of life-threatening infections associated with long-term catheter use.
What happens next
Humacyte plans to submit its FDA label expansion application to include dialysis access during the fourth quarter of 2026.
Further reading
Learn more about the latest innovations in vascular health on our Stroke page.
Live Poll
Do you trust new medical technologies over established surgical procedures for your healthcare?
